ProCE Banner Activity

Resources to Improve the Care of Patients With NSCLC and EGFR Mutations

Slideset Download
Review this slideset from a workshop series on optimal management of EGFR-mutated advanced NSCLC, including expert insights on promising investigational agents and combination therapy.

Released: September 21, 2022

Expiration: September 20, 2023

No longer available for credit.

Share

Faculty

Edward B. Garon

Edward B. Garon, MD, MS

Professor of Medicine
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Helena Yu

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Edward B. Garon, MD, MS

Professor of Medicine
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has disclosed that he has received funds for research support from ABL Bio, AstraZeneca, Bristol-Myers Squibb, Dynavax, EMD Serono, Genentech, Iovance, Lilly, Merck, Mirati, Neon, and Novartis and consulting fees from ABL Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Dracen, Eisai, EMD Serono, GlaxoSmithKline, Lilly, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, and Xilio.

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena A. Yu, MD, has disclosed that she has received funds for research support paid to her institution from AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Novartis, and Pfizer and consultant/advisor/speaker fees from AstraZeneca, Blueprint Medicine, C4 Therapeutics, Daiichi Sankyo, and Janssen Oncology.